| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Stroke. 1997;28:72-76.)
© 1997 American Heart Association, Inc.
Articles |
Thromboembolism Prophylaxis in Chronic Atrial Fibrillation
Practice Patterns in Community and Tertiary-Care Hospitals
the Department of Neurology, Buffalo General Hospital, and the School of Medicine and Biomedical Sciences of the State University of New York at Buffalo.
Correspondence to Frederick E. Munschauer, MD, WNY Neuroscience Center E2, Buffalo General Hospital, 100 High St, Buffalo, NY 14203.
Background and Purpose By 1992, several prospective trials established the efficacy of anticoagulation (AC) and to some extent antiplatelet (AP) agents in the prevention of stroke in the setting of atrial fibrillation (AF). The objective of this study was to determine whether practice patterns in AF stroke prophylaxis reflect the findings of clinical trials and whether stroke prophylaxis in AF differs between community hospitals and tertiary teaching hospitals.
Methods Retrospectively, 1250 hospital charts were reviewed. After patients who had undergone recent surgery, received treatment for malignancy, or were not in chronic AF on discharge were eliminated, 651 remaining records were analyzed for the presence of 26 clinical factors influencing the selection of thromboembolism prophylaxis. Descriptive statistics and logistic regression were used to analyze the association between clinical and demographic factors and the decision to treat with AC, AP, or no specific antiembolic therapy.
Results Of the 651 patients in AF, 273 (42%) received no emboli prophylaxis while 219 (34%) were treated with AC (warfarin), 146 (22%) were treated with AP, and 13 (2%) received both agents. Patients discharged in AF from community hospitals were significantly less likely to be treated with either AC or AP agents than patients discharged from tertiary centers. A strong bias against thromboembolism prophylaxis with either AC or AP agents in AF existed with age over 45 years. Multivariate logistic regression indicated that the decision to treat was associated only with the presence of prosthetic valve, history of prior stroke, mitral disease, and absence of a recent gastrointestinal bleed or occult blood in stool. Even after adjustment for these factors, a significant bias against treatment with either AC or AP agents with advancing age and discharge from community hospitals remained.
Conclusions Thromboembolism prophylaxis with either AC or AP agents is underutilized in the setting of AF. Furthermore, factors known to increase the risk of embolization in AF such as age, hypertension, diabetes, and heart disease were not associated with decisions to treat with either AP or AC agents. This study suggests that the use of clinical guidelines suggested by trials of thromboembolism prophylaxis in AF could reduce the incidence of stroke.
Key Words: anticoagulants • atrial fibrillation • hospitalization • quality of health care • stroke prevention • warfarin
This article has been cited by other articles:
 |
|
 |
|
  A. Meiltz, M. Zimmermann, P. Urban, A. Bloch, and on behalf of the Association of Cardiologists of t Atrial fibrillation management by practice cardiologists: a prospective survey on the adherence to guidelines in the real world Europace, June 1, 2008; 10(6): 674 - 680. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Kamohara, K. Fukamachi, Y. Ootaki, M. Akiyama, F. Cingoz, C. Ootaki, D. G. Vince, Z. B. Popovic, M. W. Kopcak Jr, R. Dessoffy, et al. Evaluation of a novel device for left atrial appendage exclusion: The second-generation atrial exclusion device. J. Thorac. Cardiovasc. Surg., August 1, 2006; 132(2): 340 - 346. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. L. Waldo, R. C. Becker, V. F. Tapson, K. J. Colgan, and for the NABOR Steering Committee Hospitalized Patients With Atrial Fibrillation and a High Risk of Stroke Are Not Being Provided With Adequate Anticoagulation J. Am. Coll. Cardiol., November 1, 2005; 46(9): 1729 - 1736. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Garcia, S. Regan, M. Crowther, R. A. Hughes, and E. M. Hylek Warfarin Maintenance Dosing Patterns in Clinical Practice: Implications for Safer Anticoagulation in the Elderly Population Chest, June 1, 2005; 127(6): 2049 - 2056. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Task Force Members, L. H. Schwamm, A. Pancioli, J. E. Acker III, L. B. Goldstein, R. D. Zorowitz, T. J. Shephard, P. Moyer, M. Gorman, S. C. Johnston, et al. Recommendations for the Establishment of Stroke Systems of Care: Recommendations From the American Stroke Association's Task Force on the Development of Stroke Systems Stroke, March 1, 2005; 36(3): 690 - 703. [Full Text] [PDF]
|
|
|
|
 |
|
 L. H. Schwamm, A. Pancioli, J. E. Acker III, L. B. Goldstein, R. D. Zorowitz, T. J. Shephard, P. Moyer, M. Gorman, S. C. Johnston, P. W. Duncan, et al. Recommendations for the Establishment of Stroke Systems of Care: Recommendations From the American Stroke Association's Task Force on the Development of Stroke Systems Circulation, March 1, 2005; 111(8): 1078 - 1091. [Full Text] [PDF]
|
|
|
|
 |
|
 R. Teng, T. C. Sarich, U. G. Eriksson, J. E. Hamer, S. Gillette, K.-M. Schutzer, G. F. Carlson Jr, and P. R. Kowey A Pharmacokinetic Study of the Combined Administration of Amiodarone and Ximelagatran, an Oral Direct Thrombin Inhibitor J. Clin. Pharmacol., September 1, 2004; 44(9): 1063 - 1071. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. K. Kapral, A. Laupacis, S. J. Phillips, F. L. Silver, M. D. Hill, J. Fang, J. Richards, J. V. Tu, and for the Investigators of the Registry of the Canad Stroke Care Delivery in Institutions Participating in the Registry of the Canadian Stroke Network Stroke, July 1, 2004; 35(7): 1756 - 1762. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L Kristensen, J C Nielsen, P T Mortensen, O L Pedersen, A K Pedersen, and H R Andersen Incidence of atrial fibrillation and thromboembolism in a randomised trial of atrial versus dual chamber pacing in 177 patients with sick sinus syndrome Heart, June 1, 2004; 90(6): 661 - 666. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. n. Garcia-Fernandez, E. Perez-David, J. Quiles, J. Peralta, I. Garcia-Rojas, J. Bermejo, M. Moreno, and J. Silva Role of left atrial appendageobliteration in stroke reductionin patients with mitral valve prosthesis: A transesophageal echocardiographic study J. Am. Coll. Cardiol., October 1, 2003; 42(7): 1253 - 1258. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Manasse, A. Barbone, F. Faletra, and R. Gallotti Microwave ablation of atrial fibrillation in conjunction with treatment of early postoperative massive left atrial thrombosis Interactive CardioVascular and Thoracic Surgery, March 1, 2003; 2(1): 16 - 18. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. A. Scott, A. M. Pancioli, L. A. Davis, S. M. Frederiksen, and J. Eckman Prevalence of Atrial Fibrillation and Antithrombotic Prophylaxis in Emergency Department Patients Stroke, November 1, 2002; 33(11): 2664 - 2669. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Wehinger, C. Stollberger, T. Langer, B. Schneider, and J. Finsterer Evaluation of Risk Factors for Stroke/Embolism and of Complications Due to Anticoagulant Therapy in Atrial Fibrillation Stroke, October 1, 2001; 32(10): 2246 - 2252. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. B. Goldstein, J. Bian, G. P. Samsa, A. J. Bonito, L. J. Lux, and D. B. Matchar New Transient Ischemic Attack and Stroke: Outpatient Management by Primary Care Physicians Arch Intern Med, October 23, 2000; 160(19): 2941 - 2946. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. J. Alberts, G. Hademenos, R. E. Latchaw, A. Jagoda, J. R. Marler, M. R. Mayberg, R. D. Starke, H. W. Todd, K. M. Viste, M. Girgus, et al. Recommendations for the Establishment of Primary Stroke Centers JAMA, June 21, 2000; 283(23): 3102 - 3109. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. E. Ansell The Quality of Anticoagulation Management Arch Intern Med, April 10, 2000; 160(7): 895 - 896. [Full Text] [PDF]
|
|
|
|
|
|
B. F. Gage, M. Boechler, A. L. Doggette, G. Fortune, G. C. Flaker, M. W. Rich, and M. J. Radford Adverse Outcomes and Predictors of Underuse of Antithrombotic Therapy in Medicare Beneficiaries With Chronic Atrial Fibrillation Stroke, April 1, 2000; 31(4): 822 - 827. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. J. Bungard, W. A. Ghali, K. K. Teo, F. A. McAlister, and R. T. Tsuyuki Why Do Patients With Atrial Fibrillation Not Receive Warfarin? Arch Intern Med, January 10, 2000; 160(1): 41 - 46. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Carlsson, S. Miketic, G. Dees, S. Haun, A. Cuneo, and U. Tebbe Stroke prevention practices in patients with atrial fibrillation and pacemaker therapy: Evidence for under-use of anticoagulation Europace, January 1, 2000; 2(2): 115 - 118. [Abstract] [PDF]
|
|
|
|
|
|
L. B. Goldstein, L. A. Hey, and R. Laney North Carolina Stroke Prevention and Treatment Facilities Survey : Statewide Availability of Programs and Services Stroke, January 1, 2000; 31(1): 66 - 70. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. S. Go, E. M. Hylek, L. H. Borowsky, K. A. Phillips, J. V. Selby, and D. E. Singer Warfarin Use among Ambulatory Patients with Nonvalvular Atrial Fibrillation: The AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study Ann Intern Med, December 21, 1999; 131(12): 927 - 934. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. J. Caro, K. M. Flegel, M.-E. Orejuela, H. E. Kelley, J. L. Speckman, and K. Migliaccio-Walle Anticoagulant prophylaxis against stroke in atrial fibrillation: effectiveness in actual practice Can. Med. Assoc. J., September 1, 1999; 161(5): 493 - 497. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. J. Connolly Preventing stroke in atrial fibrillation: Why are so many eligible patients not receiving anticoagulant therapy? Can. Med. Assoc. J., September 1, 1999; 161(5): 533 - 534. [Full Text] [PDF]
|
|
|
|
|
|
P. A. Wolf, G. P. Clagett, J. D. Easton, L. B. Goldstein, P. B. Gorelick, M. Kelly-Hayes, R. L. Sacco, and J. P. Whisnant Preventing Ischemic Stroke in Patients With Prior Stroke and Transient Ischemic Attack : A Statement for Healthcare Professionals From the Stroke Council of the American Heart Association Stroke, September 1, 1999; 30(9): 1991 - 1994. [Full Text] [PDF]
|
|
|
|
|
|
T. M. E. Davis, H. Millns, I. M. Stratton, R. R. Holman, R. C. Turner, and for the UK Prospective Diabetes Study Group Risk Factors for Stroke in Type 2 Diabetes Mellitus: United Kingdom Prospective Diabetes Study (UKPDS) 29 Arch Intern Med, May 24, 1999; 159(10): 1097 - 1103. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. HOBBS Identification and treatment of patients with atrial fibrillation in primary care Heart, April 1, 1999; 81(4): 333 - 334. [Full Text]
|
|
|
|
|
|
H R Andersen, J C Nielsen, P E B Thomsen, L Thuesen, A K Pedersen, P T Mortensen, and T Vesterlund Arterial thromboembolism in patients with sick sinus syndrome: prediction from pacing mode, atrial fibrillation, and echocardiographic findings Heart, April 1, 1999; 81(4): 412 - 418. [Abstract] [Full Text]
|
|
|
|
|
|
L. M. Brass, H. M. Krumholz, J. D. Scinto, D. Mathur, and M. Radford Warfarin Use Following Ischemic Stroke Among Medicare Patients With Atrial Fibrillation Arch Intern Med, October 26, 1998; 158(19): 2093 - 2100. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. M. Brass, H. M. Krumholz, J. M. Scinto, and M. Radford Warfarin Use Among Patients With Atrial Fibrillation Stroke, December 1, 1997; 28(12): 2382 - 2389. [Abstract] [Full Text]
|
|
|
|
|
|
H. Sievert, M. D. Lesh, T. Trepels, H. Omran, A. Bartorelli, P. Della Bella, T. Nakai, M. Reisman, C. DiMario, P. Block, et al. Percutaneous Left Atrial Appendage Transcatheter Occlusion to Prevent Stroke in High-Risk Patients With Atrial Fibrillation: Early Clinical Experience Circulation, April 23, 2002; 105(16): 1887 - 1889. [Abstract] [Full Text] [PDF]
|
|